
|Articles|March 6, 2007
siRNA candidate enters the clinic
SR Pharma has launched a Phase I clinical trial of RTP-801i.
Advertisement
SR Pharma has launched a Phase I clinical trial of RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma.
RTP-801i is based on Atugen's proprietary siRNA technology that modifies the expression of one specific gene target involved in the progression of age-related macular degeneration (AMD).
Pfizer, who licensed the product in September of last year, is funding the trial.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
Port Delivery System Therapies in Retinal Vascular Diseases
5






















